目的 探讨沙巴棕软胶囊联合特拉唑嗪治疗良性前列腺增生的临床疗效。方法 选取2017年2月-2017年6月郑州市第一人民医院收治的良性前列腺增生患者88例，随机分为对照组（44例）和治疗组（44例）。对照组睡前口服盐酸特拉唑嗪片，2 mg/次，1次/d。治疗组在对照组基础上口服沙巴棕软胶囊，160 mg/次，2次/d。两组患者均经过3月治疗。观察两组患者临床疗效，比较治疗前后两组患者前列腺体积、残余尿量、最大尿流率（Q_max）、血清指标和国际前列腺症状（IPSS）评分。结果 治疗后，对照组临床有效率为79.55%，显著低于治疗组的95.45%。两组比较差异具有统计学意义（P<0.05）。治疗后，两组前列腺体积、残余尿量均显著减小，而Q_max明显增加，同组比较差异具有统计学意义（P<0.05）；且治疗组上述指标明显好于对照组（P<0.05）。治疗后，两组血清Bcl-2、白细胞介素-6（IL-6）、IL-17水平均明显降低，IL-2水平均明显增加，同组比较差异具有统计学意义（P<0.05）；且治疗组上述指标明显优于对照组（P<0.05）。治疗后，两组患者IPSS评分均明显降低（P<0.05）；且治疗组比对照组降低的更显著（P<0.05）。结论 沙巴棕软胶囊联合盐酸特拉唑嗪片治疗良性前列腺增生可有效改善患者临床症状和细胞因子水平，具有一定的临床推广应用价值。

Objective To investigate the clinical efficacy of Sabale Soft Capsules combined with terazosin in treatment of benign prostatic hyperplasia. Methods Patients (88 cases) with benign prostatic hyperplasia in the Medical Group of Zhengzhou First People's Hospital from February 2017 to June 2017 were randomly divided into control (44 cases) and treatment (44 cases) groups. Patients in the control group were po administered with Terazosin Hydrochloride Tablets, 2 mg/time, once daily. Patients in the treatment group were po administered with Sabale Soft Capsules on the basis of the control group, 160 mg/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the prostatic volume, residual urine volume, Q_max, the serological indexes and IPSS scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 79.55%, which was significantly lower than 95.45% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the prostatic volume and residual urine volume in two groups were significantly reduced, but Q_max was significantly increased, and there were differences in the same group (P < 0.05). And these indexes in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the Bcl-2, IL-6 and IL-17 levels in two groups were significantly decreased, but IL-2 was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the serological indexes in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the IPSS score in two groups were significantly decreased (P < 0.05), and the score in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Sabale Soft Capsules combined with terazosin in treatment of benign prostatic hyperplasia can effectively improve the clinical symptoms and the cytokines level, which has a certain clinical application value.